FDA approves combo for ESR1-mutated breast cancer - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

  • By

  • Kathryn Wighton

  • September 21, 2026

  • 2 min

Share

  • 1

    The FDA approved imlunestrant with abemaciclib for adults with ESR1-mutated advanced breast cancer after prior endocrine therapy.

  • 2

    The Guardant360 CDx assay was authorized as a companion device to detect ESR1 mutations for patient selection.

  • 3

    The EMBER-3 trial involved 874 adults with estrogen receptor-positive, HER2-negative breast cancer previously treated with aromatase inhibitors.

  • 4

    Imlunestrant plus abemaciclib showed statistically significant improvement in progression-free survival compared to imlunestrant alone.

  • 5

    In patients with ESR1 mutations, median progression-free survival was 11.1 months with the combination therapy versus 5.5 months with monotherapy.

Original Source(s)

FDA approves combo for ESR1-mutated breast cancer

  • by Kathryn Wighton

  • September 21, 2026

Related Content

Do Sitting Patterns Matter?

Researchers analyzed UK Biobank data to determine whether spending sedentary time in prolonged vs interrupted bouts was associated with subsequent cancer incidence and cancer mortality.

FDA approves serial liquid biopsy testing

In SERENA-6, patients who changed treatment following detection of an ESR1 mutation had a 56% lower risk of disease progression or death.

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.